helmstar 75 wg vanddispergerbart granulat
helm ag - tribenuron-methyl, tribenuron - vanddispergerbart granulat - 750 g/kg tribenuron-methyl ; (~ 723 g/kg tribenuron
hjertemagnyl 150 mg filmovertrukne tabletter
orifarm healthcare a/s - acetylsalicylsyre - filmovertrukne tabletter - 150 mg
hjertemagnyl 75 mg filmovertrukne tabletter
orifarm healthcare a/s - acetylsalicylsyre - filmovertrukne tabletter - 75 mg
magnyl "dak" 500 mg tabletter
orifarm healthcare a/s - acetylsalicylsyre - tabletter - 500 mg
mycostop wp vanddispergerbart pulver
danstar ferment ag - streptomyces - vanddispergerbart pulver - 500000000000 cfu/kg streptomyces k61
montelukast "accord" 4 mg tyggetabletter
accord healthcare b.v. - montelukastnatrium - tyggetabletter - 4 mg
montelukast "accord" 5 mg tyggetabletter
accord healthcare b.v. - montelukastnatrium - tyggetabletter - 5 mg
xarelto
bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotiske midler - xarelto, co-gives sammen med acetylsalicylsyre (asa) alene eller sammen med asa plus clopidogrel eller ticlopidin, der er indiceret til forebyggelse af atherothrombotic hændelser hos voksne patienter efter en akut koronar syndrom (acs) med forhøjet kardiale biomarkører. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
irinotecan "accord" 20 mg/ml koncentrat til infusionsvæske, opløsning
accord healthcare b.v. - irinotecanhydrochloridtrihydrat - koncentrat til infusionsvæske, opløsning - 20 mg/ml
montelukast "stada" 10 mg filmovertrukne tabletter
stada arzneimittel ag - montelukastnatrium - filmovertrukne tabletter - 10 mg